Reducing redundant creatine kinase testing in cardiac injury

Background Creatine kinase (CK) testing in the setting of suspected cardiac injury is commonly performed yet rarely provides clinical value beyond troponin testing. We sought to evaluate and reduce CK testing coupled with troponin testing by 50% or greater.Methods We performed root cause analysis to...

Full description

Bibliographic Details
Main Authors: Dominick Shelton, Paul M Yip, Sheharyar Raza, Andre C Amaral, Jeffrey Pang, Fuad Moussa, Lowyl Notario, Heather Harrington, Jeannie L Callum
Format: Article
Language:English
Published: BMJ Publishing Group 2020-12-01
Series:BMJ Open Quality
Online Access:https://bmjopenquality.bmj.com/content/9/4/e001182.full
id doaj-e5cf905591f746a5ab54c458922971a9
record_format Article
spelling doaj-e5cf905591f746a5ab54c458922971a92021-02-01T14:00:32ZengBMJ Publishing GroupBMJ Open Quality2399-66412020-12-019410.1136/bmjoq-2020-001182Reducing redundant creatine kinase testing in cardiac injuryDominick Shelton0Paul M Yip1Sheharyar Raza2Andre C Amaral3Jeffrey Pang4Fuad Moussa5Lowyl Notario6Heather Harrington7Jeannie L Callum8Emergency Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, CanadaLaboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Ontario, CanadaInternal Medicine, University of Toronto, Toronto, Ontario, CanadaInterdepartmental Division of Critical Care, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, CanadaCardiology, Sunnybrook Health Sciences Centre, Toronto, Ontario, CanadaCardiac and Vascular Surgery, Sunnybrook Health Sciences Centre, Toronto, Ontario, CanadaEmergency Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, CanadaNursing Education, Sunnybrook Health Sciences Centre, Toronto, Ontario, CanadaLaboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Ontario, CanadaBackground Creatine kinase (CK) testing in the setting of suspected cardiac injury is commonly performed yet rarely provides clinical value beyond troponin testing. We sought to evaluate and reduce CK testing coupled with troponin testing by 50% or greater.Methods We performed root cause analysis to study prevailing processes and patterns of CK testing. We developed new institutional guidelines, removed CK from high-volume paper and electronic order bundles and conducted academic detailing for departments with highest ordering frequency. We evaluated consecutive patients at Sunnybrook Health Sciences Centre between 1 January 2018 and 31 March 2020 who had either a CK or troponin level measured. We prespecified successful implementation as a reduction of 50% in total CK orders and a decrease in the ratio of CK-to-troponin tests to one-third or less. We retained additional data beyond our study period to assess for sustained reductions in testing.Results Total CK tests decreased over the study period from 3963 to 2111 per month, amounting to a 46.7% reduction (95% CI 33.2 to 60.2; p<0.001) equalling 61 fewer tests per hospital day. Troponin testing did not significantly change during the intervention. Ratio of CK-to-troponin tests decreased from 0.91 to 0.49 (p<0.001). The reduction coincided with changes to order-sets, was observed across all clinical units and was sustained during additional months beyond the study period. These reductions in testing resulted in a projected annual cost savings of C$28 446.Conclusions We demonstrate that a low-cost and feasible quality improvement initiative may lead to significant reduction in unnecessary CK testing and substantial savings in healthcare costs for patients with suspected cardiac injury.https://bmjopenquality.bmj.com/content/9/4/e001182.full
collection DOAJ
language English
format Article
sources DOAJ
author Dominick Shelton
Paul M Yip
Sheharyar Raza
Andre C Amaral
Jeffrey Pang
Fuad Moussa
Lowyl Notario
Heather Harrington
Jeannie L Callum
spellingShingle Dominick Shelton
Paul M Yip
Sheharyar Raza
Andre C Amaral
Jeffrey Pang
Fuad Moussa
Lowyl Notario
Heather Harrington
Jeannie L Callum
Reducing redundant creatine kinase testing in cardiac injury
BMJ Open Quality
author_facet Dominick Shelton
Paul M Yip
Sheharyar Raza
Andre C Amaral
Jeffrey Pang
Fuad Moussa
Lowyl Notario
Heather Harrington
Jeannie L Callum
author_sort Dominick Shelton
title Reducing redundant creatine kinase testing in cardiac injury
title_short Reducing redundant creatine kinase testing in cardiac injury
title_full Reducing redundant creatine kinase testing in cardiac injury
title_fullStr Reducing redundant creatine kinase testing in cardiac injury
title_full_unstemmed Reducing redundant creatine kinase testing in cardiac injury
title_sort reducing redundant creatine kinase testing in cardiac injury
publisher BMJ Publishing Group
series BMJ Open Quality
issn 2399-6641
publishDate 2020-12-01
description Background Creatine kinase (CK) testing in the setting of suspected cardiac injury is commonly performed yet rarely provides clinical value beyond troponin testing. We sought to evaluate and reduce CK testing coupled with troponin testing by 50% or greater.Methods We performed root cause analysis to study prevailing processes and patterns of CK testing. We developed new institutional guidelines, removed CK from high-volume paper and electronic order bundles and conducted academic detailing for departments with highest ordering frequency. We evaluated consecutive patients at Sunnybrook Health Sciences Centre between 1 January 2018 and 31 March 2020 who had either a CK or troponin level measured. We prespecified successful implementation as a reduction of 50% in total CK orders and a decrease in the ratio of CK-to-troponin tests to one-third or less. We retained additional data beyond our study period to assess for sustained reductions in testing.Results Total CK tests decreased over the study period from 3963 to 2111 per month, amounting to a 46.7% reduction (95% CI 33.2 to 60.2; p<0.001) equalling 61 fewer tests per hospital day. Troponin testing did not significantly change during the intervention. Ratio of CK-to-troponin tests decreased from 0.91 to 0.49 (p<0.001). The reduction coincided with changes to order-sets, was observed across all clinical units and was sustained during additional months beyond the study period. These reductions in testing resulted in a projected annual cost savings of C$28 446.Conclusions We demonstrate that a low-cost and feasible quality improvement initiative may lead to significant reduction in unnecessary CK testing and substantial savings in healthcare costs for patients with suspected cardiac injury.
url https://bmjopenquality.bmj.com/content/9/4/e001182.full
work_keys_str_mv AT dominickshelton reducingredundantcreatinekinasetestingincardiacinjury
AT paulmyip reducingredundantcreatinekinasetestingincardiacinjury
AT sheharyarraza reducingredundantcreatinekinasetestingincardiacinjury
AT andrecamaral reducingredundantcreatinekinasetestingincardiacinjury
AT jeffreypang reducingredundantcreatinekinasetestingincardiacinjury
AT fuadmoussa reducingredundantcreatinekinasetestingincardiacinjury
AT lowylnotario reducingredundantcreatinekinasetestingincardiacinjury
AT heatherharrington reducingredundantcreatinekinasetestingincardiacinjury
AT jeannielcallum reducingredundantcreatinekinasetestingincardiacinjury
_version_ 1724315385427132416